For all those eye-popping fines paid by drugmakers in recent years settle to off-label marketing charges, the disclosure of government investigations into illegal promotional practices may not deter doctors from prescribing the medications for unapproved uses, according to a new study that examined prescribing data and spending for the Neurontin epilepsy medication.
As the marketing teams in the pharmaceutical industry twist themselves into pretzels trying to rework their sales efforts, a fundamental premise has been that the sales rep is going the way of Willy Loman. Or at least, most reps As always, there are numerous surveys to measure the trend, sometimes yielding differing results, and the latest shows that many doctors actually still like seeing reps.
Foster children have been prescribed psychotropic drugs - including antidepressants, antipsychotics and ADHD pills - at rates that were 2.7 times to 4.5 times higher than children not in foster homes but who received Medicaid during 2008, according to a new report from the US Government Accountability Office, which reviewed data from five states.
It is no secret that every big drugmaker is struggling to transform research and development in the wake of the infamous patent cliff and accompany pipeline problems. But how have they been faring? A new report suggests what investors have largely known - not so well. Of a dozen big drugmakers analyzed, 10 showed a decline of nearly 29 percent in their internal rate of return on R&D.
There is no debate that the Internet holds many potential riches for drugmakers seeking insights into patients. Consumers always have something to say about effectiveness and marketing. Yet many pharma folks dread combing through blogs, Facebook, forums and Twitter feeds, among other things, because they live in fear of having to file adverse event reports with the FDA.
And now, from the country that brought you the heparin scandal... The official Chinese state news agency is offering Johnson & Johnson some pointers about doing business. To be specific, the Xinhua agency is lecturing the health care giant to "practice morality" in the wake of a threatened boycott over the use of two potentially harmful chemicals in its Baby Shampoo and some other products.
As a widely anticipated FDA advisory committee meeting nears, one of the many plaintiffs in the sprawling litigation involving the Yaz and Yasmin contraceptive pills has asked a federal court for permission to provide confidential documents to the agency in the belief that these may help the panel conduct its forthcoming review of risks and benefits.
Some 40 years ago, Jim Morrison of The Doors sang that 'the future's uncertain and the end is always near.' Such a bleak philosophy may not apply to the pharmaceutical industry, but global drugmakers do have their challenges, as a new report from KPMG, which makes clear that emerging markets will certainly be a growth driver, but the not the automatic salve that some suggest.
In yet another clash between the pharmaceutical industry and the FDA over discussing prescription drug usage with doctors, Par Pharmaceutical has filed a lawsuit contending that its ability to convey "truthful" information to physicians is protected by the First Amendment, yet is thwarted by agency regulations governing off-label promotion.